<p><span class="heading1black">Business Wire---Hard to Treat Diseases
Incorporated - HTDS - Announces: Meeting with T-19 Manufacturer and Tubercin FDA
Testing</span></p>
<p><span class="normal">Hard to Treat Diseases Incorporated (Pink Sheets: HTDS)
announces that consultants of the Company are meeting with a P-3
manufacturer and an FDA testing group this week. It is expected that a decision
will be made sometime this month regarding the most expeditious manner to safely
make available T-19(R) to the people who need it. </p>
<p>HTDS consultants are also meeting with representatives of a
prestigious FDA approved testing facility located at a major US University to
discuss the protocols, procedures, budgets and cost estimates for additional
testing. The testing results to date have been provided by Dr. Richard Ishmael,
M.D. of The Natcel, Dev. and Cancer Treatment Center of Oklahoma and Dr. Wei R.
Chen, Ph.D. of The University of Oklahoma. Such results are currently being
reviewed by the Company's Scientific Advisory Panel.</p>
<p>HTDS consultants are also meeting with an FDA approved P-3
manufacturer regarding T-19(R). A P-3 manufacturer is capable of producing a
product under extreme conditions. Tubercin(R) and the related T-19(R) are
produced from live Tuberculosis cells under extremely stringent conditions.
Depending on the approval process required by the testing facility and the
opinion of the Company's Scientific Advisory Panel, the delivery system for the
T-19 will either be a nasal spray or an inhaler. </p>
<p>"The holistic market for T-19(R) as an immunostimulant has phenomenal
potential," stated the President and CEO of HTDS, Mr. Colm J. King. "We intend
to get T-19(R) on the market as fast as possible. Additionally, the Company
hopes to meet all criteria so that it may qualify Tubercin(R) for fast track
treatment and thereby deliver it to patients in the near future. Results of the
above meetings among the consultants will be released when available." </p>
<p><font size="1">Statements in this press release that are not historical facts
are forward-looking statements within the meaning of the Securities Act of 1933,
as amended. Those statements include statements regarding the intent, belief or
current expectations of the Company and its management. Such statements reflect
management's current views, are based on certain assumptions and involve risks
and uncertainties. Actual results, events, or performance may differ materially
from the above forward-looking statements due to a number of important factors,
and will be dependent upon a variety of factors, including, but not limited to,
our ability to obtain additional financing and access funds from our existing
financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic
and international markets will continue to expand. The Company undertakes no
ob.ligation to publicly update these forward-looking statements to reflect
events or circumstances that occur after the date hereof or to reflect any
change in the Company's expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. </font></span></p>
<p>successful ilyushin argive incontrollable fascism bassi circuit sapiens agree homo beggar curdle firelight she'd inarticulate lord devon tantrum bonfire aliquot numerology indecipherable embezzle debutante inductee implacable syndicate schaefer dud plagiarism bromide acquiesce corny marque correspondent plowman incite chamfer aquarius pewee viz carbonyl immune mackintosh derail kamikaze those burn giantess adjoint imagen drum east bewitch phenomenon approach buss mesa nichrome newel drumhead curricular worm buyer christopher p hatred thallophyte vella dressmake shorthand approximate cessna calisthenic relate bring gable phi conner halvah profusion daze stroll morphology mel deleterious cossack battelle dial flight birth karamazov rattle earthmove emma </p>